Brentuximab Antibody, Monoclonal | 21-857

Brentuximab Antibody, Monoclonal | 21-857 | Gentaur UK, US & Europe Distribution

Product Type: Primary Antibodies

Category: Primary Antibodies, Monoclonal Antibodies

Research Area: Drug Analogues

Type: Monoclonal

Host Species: N/A

Reactivity Species: N/A

Homology: N/A

Immunology: Humanized / TNFRSF8 (CD30, D1S166E, Ki-1) [Homo sapiens]

Tested Application: N/A

Application Note: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Predicted Molecular Weight: N/A

Isoform: N/A

Purification: >95%

Clonality: Recombinant Monoclonal

Clone: N/A

Isotype: Human IgG1

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH 7.5

Concentration: N/A

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks) . Store at -20 °C 12 months. Store at -80°C long term.

Additional Names: CD30; Ki-1; D1S166E

Protein Accession: P28908

User Note: For research use only .

Background: Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Loading Controls: N/A

Source: CHO cells

Purity: >95%

CAS: N/A

Shipping Condition: N/A